Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Alembic Pharmaceuticals Limited

http://www.alembic-india.com/

Latest From Alembic Pharmaceuticals Limited

India’s Bulk Drugs Incentive Scheme Finds First Takers

As India revealed finer details of two schemes to promote bulk drug production, Mankind Pharma and Aarti Drugs spelled out a preference for chemical synthesis products – they are likely to be joined by more companies reluctant to invest in some that are fermentation-based. Whether a “plug and play” format for bulk drug parks will attract foreign investment remains to be seen.

Manufacturing Policy & Regulation

India’s Bulk Drugs Incentive Scheme Finds Takers In Mankind, Aarti

As India revealed finer details of two schemes to promote bulk drug production, Mankind Pharma and Aarti Drugs spelled out a preference for chemical synthesis products - they are likely to be joined by more companies reluctant to invest in some that are fermentation-based. Whether a “plug and play” format for bulk drug parks will attract foreign investment remains to be seen.

Policy & Regulation Manufacturing

Early API Momentum At Indian Firms: Not Just A Quarterly Bump?

Alembic and Biocon kick off the Q1 earnings season in India with significant growth in the active pharmaceutical ingredients business and expect to see continued momentum in the area. More Indian firms could gain as customers realign strategies and move away from single sources to de-risk their supply chain, learning from pandemic-related disruptions.

Commercial Coronavirus COVID-19

Generics Industry Experiences Extraordinary First Quarter Due To COVID-19 Crisis

Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, firms have started taking precautionary measures to avoid supply-chain disruptions.

Biosimilars Business Strategies
See All

Company Information

  • Industry
  • Services
    • Hospitals, Nursing Homes, Institutions
  • Pharmaceuticals
    • Generic Drugs
  • Other Names / Subsidiaries
    • Orit Laboratories Alembic Global Holding SA Aleor Dermaceuticals Limited Alembic Pharmaceuticals Australia Pty Limited Alembic Pharmaceuticals Europe Limited Alembic Pharmaceuticals Inc Alembic Pharmacueticals Canada Limited Alnova Pharmaceuticals SA Genius LLC
UsernamePublicRestriction

Register